Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 3rd Preview)
-
FDA approval — rare disease first-in-class antisense therapy
Ionis Pharmaceuticals won FDA approval for Zanvastro, the first disease-modifying therapy for Alexander disease, in a pivotal program designed around walking speed as a core motor endpoint. The approval covers both children and adults. In the trial supporting approval, treated patients’ walking speed remained stable while those in the control group saw a 33% decline. The dataset also showed hints that earlier treatment—particularly in young children—may improve motor function rather than just slowing decline. Safety was generally manageable, with serious adverse events occurring more often in the control group than among treated patients. The approval marks a new regulatory milestone for antisense approaches in rare neurodegeneration, where options remain limited.
-
Phase 3 setback — Angelman syndrome antisense program fails
Ultragenyx said its Phase 3 study in Angelman syndrome failed to meet both primary and key secondary goals for apazunersen (GTX-102). The result sharply escalates uncertainty around the program’s endpoint strategy and its readthrough potential to other antisense candidates in development. The trial, branded Aspire, did not achieve change from baseline in the Bayley-4 Cognitive raw score at the primary endpoint and also missed net upside in the Multidomain Responder Index as a key secondary endpoint. The company said safety aligned with earlier phase data. Ultragenyx indicated it will assess next steps and pursue cost actions. The Phase 3 failure also revives scrutiny of how confirmatory trials in rare neurodevelopmental disorders are structured and interpreted after encouraging early signals.
-
Big pharma licensing deal — GSK steps further into ADCs
GSK agreed to license Hutchmed’s KRAS/EGFR antibody conjugate HMPL-A830 in a deal valued up to about $1.295 billion, plus royalties. The transaction expands GSK’s ADC ambitions beyond its current portfolio and adds a dual-target payload concept aimed at EGFR-expressing tumors. Under the terms, GSK pays $110 million upfront for the preclinical asset. The construct links an anti-EGFR antibody to a KRAS inhibitor payload designed to deliver directly to EGFR-expressing cells while simultaneously blocking EGFR and KRAS signaling. For Hutchmed, the agreement extends its external validation of its conjugate platform and underscores ongoing competition among large pharma companies to secure next-generation combination mechanisms before pipeline inflection points.
-
Phase 3 readout — Novartis remibrutinib enters relapsing MS race
Novartis’ remibrutinib delivered positive top-line Phase 3 results in relapsing multiple sclerosis, making it the second oral Bruton’s tyrosine kinase inhibitor to post favorable efficacy data in the ongoing regulatory competition. The readout positions the drug behind Roche’s fenebrutinib, as developers race to establish a first BTK inhibitor option in relapsing MS. Multiple BTK programs have faced difficulties in prior attempts, including efficacy or liver safety concerns, increasing the importance of the latest outcome. The Phase 3 signal also affects how clinicians and payers may prioritize early BTK use if confirmatory data remain favorable. The move intensifies the likelihood that the first BTK-in-MS launch will come from a narrow set of assets, with differentiation expected around long-term tolerability and biomarker-aligned response rates.
-
Big pharma delivery deal — Novartis licenses Alteogen’s ALT-B4
Novartis agreed to use Alteogen’s Hybrozyme-based ALT-B4 enzyme platform to support subcutaneous delivery of multiple biologics, in a deal worth up to $3.2 billion. The agreement underscores continued shift by large pharma toward enabling faster, less burdensome dosing than intravenous administration. ALT-B4 (berahyaluronidase alfa) is designed to transiently break down hyaluronan in the extracellular matrix under the skin, allowing co-administered biologics to disperse and absorb more rapidly. Option rights cover development and commercialization of subcutaneous formulations across several products. AstraZeneca and GSK/Tesaro previously executed similar licensing paths for ALT-B4, reinforcing that delivery-enabling assets are becoming central to biopharma product strategy as companies seek to improve treatment convenience without changing core modalities.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.